ViGeneron
Business Services · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Semmelweisstraße 3, Planegg, Bavaria, 82...Phone Number
+49 89693148900Website
www.veongen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About ViGeneron
VeonGen Therapeutics is a next-generation gene therapy company focused on developing innovative therapies for ophthalmic diseases with high unmet medical needs. Their proprietary vector platforms, including vgAAV and vgRNA REVeRT, aim to enhance gene delivery and overcome existing limitations in gene therapy. The company is also exploring partnerships with biopharmaceutical players to apply their technology in other disease areas such as neuroscience, diabetes, and cardiovascular diseases. VeonGen's pipeline includes lead programs targeting inherited retinal diseases where no approved treatments are currently available.Explore more
Popular SearchesVigeneronViGeneron GmbHSIC Code 87,873NAICS Code 54,541Show moreViGeneron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ViGeneron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ViGeneron is spiking on competitors!
Earning: See what the market has to say on ViGeneron recently announced quarterly report
Product Launch: Get notified when ViGeneron launches new products
ViGeneron, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ViGeneron has recently received funding, and reach out quickly before it becomes old news!
Click to see if ViGeneron had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once ViGeneron has new funding data
Congratulate Masked Content for being promoted to Masked Content at ViGeneron
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
ViGeneron is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ViGeneron is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ViGeneron.
ViGeneron Tech Stack
A closer look at the technologies used by ViGeneron
See more technologies
Most Recent Scoops
Project
Research & Development, Compliance, Medical Research, Pharmaceuticals, Regulations
Project
Research & Development, Compliance, Medical Research, Pharmaceuticals, Regulations
Funding
Funding
Funding
ViGeneron News & Media
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
MUNICH, June 05, 2025 (GLOBE NEWSWIRE) -- VeonGen Therapeutics, formerly known as ViGeneron, today announced its rebranding to reflect its evolution into a clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs.ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial
MUNICH, Jan. 08, 2025 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a next-generation clinical-stage gene therapy company, today announced two important milestones for its novel gene therapy candidate VG901, to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to VG901, and the independent Data Safety Monitoring Board (DSMB) has unanimously approved dose escalation in the onViGeneron Announces FDA Clearance of IND for Novel mRNA Trans-Splicing Gene Therapy VG801 to Treat Stargardt Disease and Other ABCA4-Linked Retinal Dystrophies
MUNICH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a next-generation clinical-stage gene therapy company, today announced that the United States Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Phase I/II study of VG801, a potentially transformative gene therapy to treat Stargardt disease and other retinal dystrophies associated with mutations in the ABCA4 gene.ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa
MUNICH, Germany, April 10, 2024 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a next-generation clinical-stage gene therapy company, today announced that the first patient has been dosed in its Phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. This milestone marks an important advance as the company continues to leverage its next-generation technology platforms to develop groundbreaking gene therapies addressing cri
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding ViGeneron
Sign Up For FreeTo access detailed company insights
VeonGen Therapeutics is a next-generation gene therapy company focused on developing innovative therapies for ophthalmic diseases with high unmet medical needs. Their proprietary vector platforms, including vgAAV and vgRNA REVeRT, aim to enhance gene delivery and overcome existing limitations in gene therapy. The company is also exploring partnersh... Read More
